Catalyst Brief

← Calendar

Readoutin 13d

Gilead Sciences — Sacituzumab Govitecan-hziy

Phase 3 primary completion: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC).

Date
Dec 2026
Type
Readout
Indication
Metastatic Breast Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Gilead Sciences

  1. Feb2027